Stellar Murumba has been investigating substandard antimalarial drugs. Her work has led to the Kenyan Health Ministry to recall Duo-Cotecxin, a commonly used antimalarial.
Dr Deborah O’Neil is the CEO of Novabiotics, a leading clinical-stage biotechnology company. She talks to me about antibiotic resistance and the future of pharma with so-called ‘personalised medicines’.
Dr Michelle Wykes runs the Molecular Immunology unit at QIMR Berghofer Medical Research Institute and has been focusing on trying to improve the immune system’s response to a malaria infection. We discuss her recent work in malaria research which has been hailed as a breakthrough.
We speak with John Dowe of the International Mefloquine Veterans Alliance. The Alliance is a network of individuals affected by the health impacts of Mefloquine and Tafenoquine. Their aim is to support those who are dealing with the complex health implications of the drug’s toxicity.
As part of our ongoing podcast series investigating the antimalarial drugs Tafenoquine and Mefloquine, I speak with Professor Jane Quinn, an army widow. She shares her personal experience with Mefloquine and tells me what kind of side effects an individual may experience from taking the drug.
Tafenoquine is safe and effective, according to the Australian researcher, Professor James McCarthy. He tells us how Tafenoquine and Mefloquine are very different in how they interact with the body.
Meet the man that opposes the use of Tafenoquine. Dr Remington Nevin runs an organisation lobbying against the use of Tafenoquine and other Quinolines. In this interview, he tells us the real reason for why GSK and 60 Degrees are developing the drug, which the U.S. army abandoned (it’s to do with money).
We speak with Professor Jake Baum of Imperial College London. He has been thrust in the spotlight for what the ‘Independent’ is calling a ‘major malaria breakthrough’. His team is working on trying to find a set of compounds that stop mosquitoes from contracting malaria when they bite an infected person.